BDNF release is required for the behavioral actions of ketamine. - Wikidata - awgldk - TriplyDB

BDNF release is required for the behavioral actions of ketamine.

BDNF release is required for the behavioral actions of ketamine.

http://www.wikidata.org/entity/Q35203597

about

Rett Syndrome: Crossing the Threshold to Clinical Translation Antidepressant mechanism of ketamine: perspective from preclinical studies R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression NMDAR inhibition-independent antidepressant actions of ketamine metabolites.Rapid Antidepressant Activity of Ethanol Extract of Gardenia jasminoides Ellis Is Associated with Upregulation of BDNF Expression in the Hippocampus.The Combination of Long-term Ketamine and Extinction Training Contributes to Fear Erasure by Bdnf Methylation.Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.Spine synapse remodeling in the pathophysiology and treatment of depression.Pathogenesis of depression: Insights from human and rodent studies.Neuronal correlates of depression."Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?"BDNF - a key transducer of antidepressant effects.The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model Neurotrophin signalling: novel insights into mechanisms and pathophysiology.Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.BDNF in sleep, insomnia, and sleep deprivation.KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.Pushing the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy depression.On the Eve of Upgrading Antidepressants: (R)-Ketamine and Its Metabolites.Identifying fast-onset antidepressants using rodent models.Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling.Neuronal plasticity and neurotrophic factors in drug responses.Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.Subanesthetic ketamine decreases the incentive-motivational value of reward-related cues.BDNF release and signaling are required for the antidepressant actions of GLYX-13.Behavioral and biochemical sensitivity to low doses of ketamine: Influence of estrous cycle in C57BL/6 mice.Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.Engaging homeostatic plasticity to treat depression.VGF function in depression and antidepressant efficacy.The requirement of L-type voltage-dependent calcium channel (L-VDCC) in the rapid-acting antidepressant-like effects of scopolamine in mice.BDNF at the synapse: why location matters.Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.

P2860

Q26772909-F2735491-3B10-400C-8243-D289CA6B4891 Q26800231-D7437D33-DC9F-4A2F-8D8C-BC5F870985A0 Q28266846-C7DB11F2-A8D9-41C7-8DFF-70061B1E0D55 Q28277636-6DB35E5C-4B62-439B-B45F-36CE23A43ED9 Q30370600-A866E270-1393-41B2-B528-604191E95974 Q30414296-A16C6D2E-15B4-4D38-94D1-AEE5E0924F95 Q33583121-3D1FAA5D-28FC-4905-A753-77164F589691 Q33614178-0DAD60C5-4AE5-4FF8-8D0F-CF8AF6F9AB46 Q33879254-3F26154E-7E68-4C57-B08D-EA618107A2D3 Q34492381-14F647F6-6934-4235-84EE-C11556640558 Q34512818-FCF28EF7-63B9-4513-AB8A-F9CA7CAA6D11 Q35836787-ECCD66E6-96DB-4A7C-BD71-DAF34992276F Q36332597-969AE413-381C-45E8-B4D4-5978788865C5 Q36451816-C0E6132C-551E-40A3-824A-E115F3A56A07 Q36603490-3188C879-D56E-4832-A2FC-C6CD34C879B1 Q36608239-70F387E1-F89E-47DD-A89F-90F215B46933 Q36754254-0688BC6A-B19C-4AEA-9E13-E62AA003A454 Q36915463-D30B5669-9388-4420-BA32-78AB567572BB Q37629100-476C3DF3-F7EA-49A1-B14F-A22B6904C44B Q37668009-6B8390EB-E718-420B-AB1D-280DF300896D Q37722650-6E96D7D6-2243-4C4B-8EE2-9AF3F9EFF87D Q38693724-6A190948-F972-4CDD-8FDD-410D992EA9CF Q38803371-0D5929D4-E99E-47CB-B2CC-CBAAEE8816F2 Q38820173-7376EC95-D690-405A-B08C-889413A94D7F Q39008886-0DB4964A-2BFE-4936-8E99-340B189956B9 Q39189493-5BA09AA9-CC8D-42DA-924A-7033532E8AAA Q39494795-621B3779-3CFC-414C-B5A5-54893C4C94E3 Q41842609-0D33F920-9F04-46B5-AB57-295383BDFF5D Q42034477-F8CD3C86-7DE8-4C7E-980C-FF587F5FD186 Q46139260-BC416CB4-DB47-4145-845C-FA7F51D9FC41 Q47151084-FFA4F0A7-9E53-4467-8AAE-A5A2A09CC17E Q47331962-926FB5D4-0E3C-4400-BEB0-C9EA4EF39EF0 Q47365024-22E21308-9BAE-434A-9768-4849342E3B2C Q47388230-8CC04E64-AC59-4931-BA1B-088214B04920 Q47396901-0F4A58DC-6877-43D7-A594-BE67FE34694B Q47406465-DEE2FF3A-4D24-422A-B2BC-504111E6E047 Q47574847-4D1E07AF-CFDA-47B0-92AD-6890A7769217 Q47742617-746E97B5-96EB-4030-BCAD-EC3CE2F2027B Q47762461-B1A4C7C3-EE60-423A-8C63-44299CAC1E33 Q47814036-19C7CB75-42EB-41A3-8A9C-03E405DAC5B2

P2860

BDNF release is required for the behavioral actions of ketamine.

http://www.wikidata.org/entity/Q35203597

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

BDNF release is required for the behavioral actions of ketamine.

@ast

BDNF release is required for the behavioral actions of ketamine.

@en

type

label

BDNF release is required for the behavioral actions of ketamine.

@ast

BDNF release is required for the behavioral actions of ketamine.

@en

prefLabel

BDNF release is required for the behavioral actions of ketamine.

@ast

BDNF release is required for the behavioral actions of ketamine.

@en

P1433

Q35203597-4CB886B4-7E75-43A4-876A-F2763439EB50

P1476

Q35203597-C9C01D9C-CB0E-418B-A550-F2277E7719E4

P2093

Q35203597-5CECAE2C-E916-4A69-BC75-79B3649F2D71

Q35203597-8589A088-3F86-4AC7-9D3A-FC117D6CB984

Q35203597-9627A712-D657-4389-B5CA-611C9F74CC47

Q35203597-A382AB3D-18D5-4568-A006-E2671B06C6FB

Q35203597-E895F940-9E0F-41DA-87B4-23CF7E0071AF

P2860

Q35203597-07CF471E-A7CF-47E7-9801-75F12266D8B2

Q35203597-0B391916-EA10-42E3-8EBF-5AD683746331

Q35203597-1CA4B44D-3BA0-48FB-8530-87791EAF725D

Q35203597-1D37515A-8F9E-4275-A582-83F5EFF275EE

Q35203597-1E23094F-2004-4DE6-BA60-D822E3743D8E

Q35203597-303C1145-FADB-4212-9551-91F1DD54A73E

Q35203597-32D35949-9461-4C99-96F5-25AB20F274AE

Q35203597-36B9A807-9D3C-4F86-94BD-F504752EC91B

Q35203597-44D8FB7D-B977-4BE1-BDEE-7E9B19250B04

Q35203597-5CB643BA-513F-4B79-AEB8-656636B9B831

P31

Q35203597-E8D99567-A92C-483F-B225-2E16B3614514

P356

Q35203597-AD539B40-20E0-4002-BFDA-9E2546E0B282

P433

Q35203597-AFD27E39-EEE5-492E-B979-3DF31AB28A0E

P478

Q35203597-944A9F65-48DF-4F94-A04F-BBB5228FA42A

P577

Q35203597-DC85B6AA-A19C-4BDC-982C-AFA0510CE0CA

P5875

Q35203597-D982184E-2975-428B-92AA-79D4217E9634

P698

Q35203597-10F793AE-C743-4BEA-A3E6-EBA1F7EEC7EF

P932

Q35203597-7E9B2CD0-01B1-46CC-8ACA-280A9FF51DDF

P356

P1433

The International Journal of Neuropsychopharmacology

P1476

BDNF release is required for the behavioral actions of ketamine.

@en

P2093

Ashley E Lepack

http://www.w3.org/2001/XMLSchema#string

Jason M Dwyer

http://www.w3.org/2001/XMLSchema#string

Manabu Fuchikami

http://www.w3.org/2001/XMLSchema#string

Mounira Banasr

http://www.w3.org/2001/XMLSchema#string

Ronald S Duman

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade

Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation

BDNF activates mTOR to regulate GluR1 expression required for memory formation

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

A neurotrophic model for stress-related mood disorders

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

P31

scholarly article

P356

10.1093/IJNP/PYU033

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270107357

http://www.w3.org/2001/XMLSchema#string

P698

25539510

http://www.w3.org/2001/XMLSchema#string

P932

4368871

http://www.w3.org/2001/XMLSchema#string